Progress toward a pathogen-free blood supply

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 88-95

  McCullough, Jeffrey ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMATOSALEN; CHOLIC ACID; ENVELOPE PROTEIN; METHYLENE BLUE; PHOSPHATE; PLASMA PROTEIN; PSORALEN DERIVATIVE; SOLVENT; TRINITROBUTYL PHOSPHATE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

BACTERIAL INFECTION; BLOOD BANK; BLOOD DONOR; BLOOD TRANSFUSION; CELL INCLUSION; CLINICAL TRIAL; DISEASE TRANSMISSION; ERYTHROCYTE; EUROPE; EVALUATION; GENE REPLICATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LABORATORY TEST; MUTAGENICITY; NUCLEIC ACID ANALYSIS; PHOTOTOXICITY; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTOZOAL INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; SCREENING; TECHNIQUE; THROMBOCYTE; UNITED STATES; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS VIRULENCE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; BLOOD; BLOOD BANKS; BLOOD DONORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CHEMOPREVENTION; HUMANS; VIRUS DISEASES;

EID: 0037897338     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375232     Document Type: Review

References (57)

1. McCullough J. The nation's changing blood supply system. JAMA 1993; 269:2239-45.
2. McCullough J. The continuing evolution of the nation's blood supply system. Am J Clin Path 1996; 105:689-95.
3. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate and window-period model [editorial]. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study. Transfusion 2002; 42:966-73.
4. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
5. Klein HG. Will blood transfusion ever be safe enough? JAMA 2000; 284:238-40.
6. Busch MP, Kleinman SH, Stramer SL. Nucleic acid amplification testing of blood donations. In: Sibinga S, Klein HG, eds. Molecular biology in blood transfusion. Dordrecht, Netherlands: Kluwer Academic Publications, 2000:81-103.
7. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. JAMA 2000; 284:229-35.
8. Schreiber GB, Busch MP, Kleinman SH. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334:1685-90.
9. Busch M, Chamberland M, Epstein J, Kleinman S, Khabbaz R, Nemo G. Oversight and monitoring of blood safety in the United States. Vox Sang 1999; 77:67-76.
10. Stramer SL, Caglioti C, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165.
11. Klein HG, Dodd RY, Ness PM, Fratantoni JA, Nemo GJ. Current status of microbial contamination of blood components: summary of a conference. Transfusion 1997; 37:95-101.
12. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41:857-61.
13. Roth VR, Kuehnert MJ, Haley NR, et al. Evaluation of a surveillance system for bacterial contamination of blood and blood products in the United States. Transfusion 2001; 41:1486-92.
14. Prince AM, Horowitz B, Brotman B. Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1986; 1(8483):706.
15. Horowitz B, Bonomo R, Prince AM, Sing NC, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79:826-31.
16. Inbal A, Epstein O, Blickstein D, Kornbrot N, Brenner B, Martinowitz U. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993; 4:599-604.
17. Klapper E, Goldfinger D, Jacobs A, Zarou C, Pehta J. Safety and efficacy of solvent detergent treated plasma in patients with end stage liver disease or factor XI deficiency. Transfusion 1996; 36:125.
18. Moake J, Chintagumpala M, Turner N, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84:490-7.
19. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000; 40:1203.
20. Pooled Solvent Detergent Treated Plasma PLAS + SD. Watertown, MA: V.I. Technologies; 2002.
21. Müller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol 1998; 56:239-45.
22. Morado M, Villar A, Jimenez-Yuste VM, et al. Effects of methylene blue-treated plasma on coagulation factors [abstract]. Blood 1999; 94: 247a.
23. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38:4-11.
24. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37:423-35.
25. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfin. Transfusion 2002; 42:1302-7.
26. Wages D, Smith D, Walsh J, et al. Transfusion of therapeutic doses of virally inactivated fresh frozen plasma in healthy subjects [abstract]. Blood 1997;90:409a.
27. Corten L, Wiesehahn GP, Smyers JM, Murthy KK, McClure HM, Alter HJ. Photochemical inactivation of hepatitis B and hepatitis C viruses in human plasma as assessed in a chimpanzee infectivity model [abstract]. Blood 2000; 96:60a.
28. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx component: a clinical perspective. Semin Hematol 2001; 38:12-9.
29. Wages DC, Bass N, Keefe E, et al. Treatment of acquired coagulopathy by transfusion of fresh frozen plasma (FFP) prepared using a novel, single unit photochemical pathogen inactivation process [abstract]. Blood 1999; 94:247a.
30. deAlercon P, Benjamin R, Shopnick R, et al. An open-label trial of fresh frozen plasma treated by the Helinx single-unit photochemical pathogen inactivation system in patients with congenital coagulation factor deficiencies [abstract]. Blood 2000; 96:61a.
31. Corash L, Behrman B, Rheinschmidt M, et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates [abstract]. Blood 1997; 90:267a.
32. Slichter SJ, Corash L, Grabowski M, et al. Viability and hemostatic function of photochemically-treated platelets in thrombocytopenic patients [abstract]. Blood 1999; 94:376a.
33. Murphy S, Heaton WA, Rebulla P. Platelet production in the old world - and the new. Transfusion 1996; 36:751-4.
34. Van Rhenen D, Gulliksson H, Phamphilon D, et al. S-59 (Helix) photochemically treated platelets are safe and effective for support of thrombocytopenia: results of the eurosprite phase 3 trial [abstract]. Blood 2000; 96:819a.
35. McCullough J, Vesole D, Benjamin RJ, et al. Pathogen inactivated platelets using Helinx technology (INTERCEPT) are hemostatically effective in thrombocytopenic patients: the SPRINT trial [abstract]. Blood 2001; 98:450a.
36. Purmal A, Valeri CR, Dzik W, et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002; 42:139-45.
37. Edson CM, Purmal A, Brown F, Valeri CR, Budowsky E, Chapman JR. Viral inactivation of red blood cell concentrates by Inactine: mechanism of action and lack of effect on red call physiology [abstract]. Transfusion 1999; 39:108s.
38. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sang 2000; 78:203-4.
39. Cook D, Stassinopoulos A, Merritt J, et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303 [abstract]. Blood 1997; 90:409a.
40. Cook D, Stassinopoulos A, Wollowitz S, et al. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens [abstract]. Blood 1988; 92:503a.
41. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sang 2000; 78:205-10.
42. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta 1965; 103:360-3.
43. Korycka-Dahl M, Richardson T. Photodegradation of DNA with fluorescent light in the presence of riboflavin and photoprotection by flavin triplet-state quenchers. Biochim Biophys Acta 1980; 610:229-34.
44. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78:211-5.
45. Wagner SJ, Skirpchenko A, Robinette D, Mallory DA, Cincotta L. Preservation of red cell properties after virucidal phototreatment with dimethylene blue. Transfusion 1998; 38:729-37.
46. Workshop on Development of Donor Screening Assays for West Nile Virus - 4-5 November 2002. Available at: http://www.fda.gov/cber/ minutes/workshop-min.htm#screenwnv. Accessed 20 June 2003.
47. Brown P. Transfusion medicine and spongiform encephalopathy. Transfusion 2001; 41:433-6.
48. Chapman J, Purmal A, Dzik W. Preclinical safety assessment of red cells virally inactivated by inactine: lack of neoantigenicity [abstract]. Blood 2000; 96:61a.
49. Aubuchon AP, Pickard CA, Herschel LH, et al. In vivo recovery of red blood cells virally inactivated by INACTINE and stored for 28 days [abstract]. Blood 2000; 96:818a.
50. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a phase I clinical study. Transfusion 2002; 42:146.
51. Greenwalt TJ, Hambleton J, Wages D, et al. Viability of red blood cells treated with a novel pathogen inactivation system [abstract]. Transfusion 1999; 39:109s.
52. Hambleton J, Greenwalt T, Viele M, et al. Post transfusion recovery after multiple exposure to red blood cell concentrates (RBCs) treated with a novel pathogen inactivation process [abstract]. Blood 1999; 94: 376a.
53. Fast L, DiLeone G, Edson C. Treatment of human leuckocytes with inactine results in loss of function and induction of apoptosis [abstract]. Blood 2000; 96:61a.
54. Fast LD, DiLeone G, Edson CM, Purmal A. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to gamma irradiation. Transfusion 2002; 42: 1318-25.
55. Fast LD, Dileone G, Edson CM, Purmal A. Inhibition of murine GVHD by PEN110 treatment. Transfusion 2002; 42:1326-32.
56. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998; 91:2180-8.
57. Deeg HJ. Transfusions with a tan: prevention of allosensitization by ultraviolet irradiation. Transfusion 1989; 29:450.